Phage Therapy Kits Market - Global Forecast 2026-2032

The Phage Therapy Kits Market size was estimated at USD 428.13 million in 2025 and expected to reach USD 520.92 million in 2026, at a CAGR of 21.73% to reach USD 1,696.24 million by 2032.

Phage therapy kits are emerging as a pivotal innovation in the fight against antibiotic-resistant infections, marking a significant evolution in antimicrobial strategies. These kits combine bacteriophage isolation tools, purification reagents, and standardized quantitative assays to enable research laboratories and clinical settings to develop, test, and apply phage-based interventions. Over the past decade, academic and biopharmaceutical research efforts have converged on phage therapy as a precision medicine approach, leveraging the natural specificity of bacteriophages to target pathogenic bacteria without disrupting the host microbiome. This shift reflects growing recognition of phages not only as therapeutic agents but also as essential components of diagnostic workflows and quality assurance processes in both industrial and healthcare contexts. As regulatory bodies worldwide accelerate their frameworks for advanced biologics, the availability of end-to-end kits for phage isolation, characterization, and quantification is catalyzing new collaborative efforts between kit manufacturers, academic research groups, and biotech startups.

Breakthrough innovations in genetic engineering and synthetic biology have propelled phage therapy kits from experimental concepts to commercially viable solutions, fueling a transformative shift across the life sciences sector. Advances in CRISPR‐based editing have enabled the design of customized phage platforms with enhanced host specificity and immune evasion capabilities, facilitating more predictable clinical outcomes. Concurrently, the integration of next‐generation sequencing modules into reagent kits has streamlined the rapid identification of phage–bacteria interactions, empowering researchers to tailor phage libraries for complex infection profiles. These technical milestones are complemented by emerging frameworks for good manufacturing practice (GMP) production, with several manufacturers securing facility validations that align with both FDA and EMA guidelines, thereby reducing time‐to‐market for therapeutic and diagnostic applications.

Recent tariff adjustments enacted by the United States Trade Representative under Section 301 and other trade measures are exerting significant influence on the cost structure for phage therapy kits, particularly those components reliant on imported consumables and instrumentation. Consumable items such as lysis buffers, staining reagents, and specialized control panels often originate from China, where Section 301 tariffs ranging between 25 percent and 100 percent on medical device imports have been implemented, notably affecting reagents grouped under HTS 9018.31.0080 and related codes. These additional duties have translated into higher landed costs for complete kits and individual reagent components, compelling manufacturers to reassess supply chain strategies and explore near‐sourcing options in Mexico and Canada to mitigate tariff exposure and maintain competitive pricing for research and therapeutic end users.

In‐depth analysis of application domains underscores that phage therapy kits are tailored for diverse uses, extending from agricultural pathogen control to food safety assays, and into specialized research and therapeutic segments. Within the research sphere, demand bifurcates between basic academic investigations and commercial R&D laboratories, each requiring bespoke platforms for phage library expansion and high‐throughput screening. Clinical therapeutic applications further segment into infectious disease interventions, oncology adjunct therapies, and wound healing protocols, with sub‐specializations in gastrointestinal infections and hospital‐acquired infection management. Complementing this, kit architectures vary from fully integrated systems with standardized consumables to modular reagent sets that include negative and positive controls alongside lysis buffers and staining reagents. End users span biopharmaceutical manufacturers, diagnostic centers, hospitals, and research laboratories, the latter comprising both academic institutions and contract research organizations offering clinical and preclinical services. Delivery modules influence kit design, with injection methods-whether intramuscular, intravenous, or subcutaneous-dictating sterility and formulation requirements, while oral and topical formats demand distinct stability and bioavailability profiles. Finally, product portfolios encompass diagnostic, purification, quantification, and sequencing kits, with quantification tools subdivided into plaque assay and qPCR formats, the latter differentiated by probe‐based and Sybr Green chemistries.

Across the Americas, established research hubs in North America are driving kit adoption through robust investments in academic‐industry partnerships and federal funding initiatives targeting antimicrobial resistance. In the United States, regulatory clarity from the FDA around compassionate use protocols and streamlined investigational new drug submissions has fostered confidence in phage therapy commercialization, while Canadian centers leverage collaborative grants to integrate phage quantification kits into food safety monitoring programs. Shifts in Latin American policy frameworks and expanding technical training networks are further accelerating kit deployments in agricultural and diagnostic contexts.

Leading life sciences companies are solidifying their positions by forging strategic alliances and expanding phage kit portfolios to encompass both research and therapeutic domains. BiomX’s positive Phase 2 data on osteomyelitis treatments underscore the translational potential of integrated phage delivery systems, while Armata’s merger history and pipeline expansion reflect a focus on cocktail‐based therapies for chronic pulmonary and implant‐associated infections. Phaxiam Therapeutics, born from a European merger, exemplifies cross‐border consolidation aimed at scaling GMP production capabilities. Novel entrants such as Locus Biosciences and SNIPR Biome are leveraging CRISPR‐enhanced phages and synthetic biology platforms to differentiate their reagent and sequencing kits, and firms like ContraFect are pursuing lysin‐based modules that complement traditional phage approaches, broadening the competitive landscape.

To navigate the evolving phage therapy kit ecosystem, industry leaders should prioritize diversified sourcing for critical reagents and packaging components to insulate against tariff volatility and global supply disruptions. Engagement with regulatory authorities through pre‐submission meetings and joint collaboration forums can accelerate clarity around quality standards, reducing time‐to‐market for both therapeutic and diagnostic kit releases. Investing in modular manufacturing lines capable of rapid format switching ensures responsiveness to emerging clinical needs, while forging partnerships with academic centers and contract research organizations will amplify access to novel phage libraries and validation models. Finally, integrating advanced data analytics into kit platforms can deliver actionable insights on phage–bacteria dynamics and support personalized treatment regimens.

This report’s findings are based on a rigorous mixed‐methodology research approach, combining primary interviews with leading phage biologists, clinical investigators, and kit manufacturing executives, alongside secondary data collection from peer‐reviewed journals, regulatory filings, and patent databases. Triangulation of insights was achieved through detailed vendor profiling, financial disclosures, and analysis of clinical trial registries to map pipeline dynamics and technology readiness levels. Market segmentation was validated through expert panels, and forecast assumptions were stress‐tested under various supply chain and policy scenarios to ensure robustness.

Phage therapy kits stand at the cusp of mainstream adoption, underpinned by technological advancements, regulatory momentum, and mounting clinical evidence. Although challenges persist-from tariff‐driven cost pressures to the complexity of multi‐phage formulations-the convergence of synthetic biology, precision engineering, and global harmonization efforts signals a turning point for antibacterial innovation. As phage kit platforms evolve to meet diverse application needs across agriculture, diagnostics, and therapeutics, stakeholders equipped with comprehensive market intelligence will be best positioned to harness the full potential of this emerging frontier.

To explore how these insights translate into strategic advantage and to secure comprehensive access to our full market research report, please reach out to Ketan Rohom, Associate Director of Sales & Marketing at 360iResearch. He can guide you through tailored data solutions, licensing options, and bespoke consultation packages that align with your organization’s unique objectives. Engage directly with Ketan Rohom to obtain in-depth analyses, proprietary data libraries, and expert advisory services that will empower your team to make informed decisions and capitalize on emerging opportunities in the phage therapy kits landscape. Don’t miss the chance to gain a competitive edge-contact Ketan today to request a personalized briefing and unlock the complete report.